COMPANY

Luxa Biotechnology

Keywords: geographic atrophy Dry Age-related Macular Degeneration RPESC-RPE-4W

Location: Fort Lee, NJ · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Apr 5, 2022 Trial start Phase 1/Phase 2: Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) source ↗

Dec 1, 2026 (ESTIMATED) · Phase 1/Phase 2 · Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) · NCT04627428

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT04627428	Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)	Phase 1/Phase 2	Recruiting	Apr 5, 2022	Dec 1, 2026 (estimated)